ME3

Across TCGA pan-cancer cohorts, ME3 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of ME3’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where ME3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ME3 is over-expressed in tumor, although a few such as HNSC and UCEC show the opposite, repressed pattern.

THCA, HNSC, and LIHC are the cancer types where ME3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ME3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	All	+0.970	<.001	9	view →
HNSC	Male	All	−0.925	<.001	9	view →
LIHC	All	II,III,IV	+1.143	<.001	8	view →
KICH	Female	II,III,IV	+1.114	<.001	8	view →
UCEC	All	All	−1.209	<.001	6	view →
BRCA	Female	All	−1.188	<.001	6	view →
LUSC	Male	II,III,IV	−1.186	<.001	6	view →
BLCA	Male	All	−0.898	.004	6	view →
KIRP	Male	All	−0.748	<.001	6	view →
LUAD	Male	All	+0.575	<.001	5	view →
COAD	All	All	+0.344	.002	4	view →
KIRC	All	II,III,IV	−0.279	.004	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

ME3–THCA

Open the THCA breakdown →